Vernalis and Asahi Kasei Pharma Achieve Research Milestone

Vernalis is pleased to announce the achievement of the second milestone in its drug discovery collaboration with Asahi Kasei Pharma (AKP). Vernalis will receive a payment of £0.5m in recognition of this achievement.

This collaboration with AKP was initiated in October 2013 and utilises Vernalis' fragment and structure-based drug discovery platform against an undisclosed target for rheumatoid arthritis and other autoimmune diseases. Overall financial terms of this collaboration have not been disclosed.